Kate Hanneman1, Christian Houbois1,2, Alice Schoffel3, Dakota Gustafson4, Robert M Iwanochko3, Bernd J Wintersperger1, Rosanna Chan1, Jason E Fish4, Kathryn L Howe5, Paaladinesh Thavendiranathan1,3. 1. Department of Medical Imaging, Toronto General Hospital, Peter Munk Cardiac Center, University Health Network (UHN), University of Toronto, Toronto, Ontario, Canada. 2. Department of Diagnostic and Interventional Radiology, University of Cologne, Cologne, Germany. 3. Division of Cardiology, Peter Munk Cardiac Centre, Toronto General Hospital, University Health Network (UHN), University of Toronto, Toronto, Ontario, Canada. 4. Toronto General Hospital Research Institute, University Health Network (UHN), Department of Laboratory Medicine & Pathobiology, University of Toronto, Toronto, Ontario, Canada. 5. Department of Vascular Surgery, Toronto General Hospital, University Health Network (UHN), University of Toronto, Toronto, Ontario, Canada.
Abstract
IMPORTANCE: Although myocardial injury can occur with acute COVID-19, there is limited understanding of changes with myocardial metabolism in recovered patients. OBJECTIVE: To examine myocardial metabolic changes early after recovery from COVID-19 using fluorodeoxyglucose-positron emission tomography (PET) and associate these changes to abnormalities in cardiac magnetic resonance imaging (MRI)-based function and tissue characterization measures and inflammatory blood markers. DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort study took place at a single-center tertiary referral hospital system. A volunteer sample of adult patients within 3 months of a diagnosis of COVID-19 who responded to a mail invitation were recruited for cardiac PET/MRI and blood biomarker evaluation between November 2020 and June 2021. EXPOSURES: Myocardial inflammation as determined by focal fluorodeoxyglucose (FDG) uptake on PET. MAIN OUTCOMES AND MEASURES: Demographic characteristics, cardiac and inflammatory blood markers, and fasting combined cardiac 18F-FDG PET/MRI imaging were obtained. All patients with focal FDG uptake at baseline returned for repeated PET/MRI and blood marker assessment 2 months later. RESULTS: Of 47 included patients, 24 (51%) were female, and the mean (SD) age was 43 (13) years. The mean (SD) interval between COVID-19 diagnosis and PET/MRI was 67 (16) days. Most patients recovered at home during the acute infection (40 [85%]). Eight patients (17%) had focal FDG uptake on PET consistent with myocardial inflammation. Compared with those without FDG uptake, patients with focal FDG uptake had higher regional T2, T1, and extracellular volume (colocalizing with focal FDG uptake), higher prevalence of late gadolinium enhancement (6 of 8 [75%] vs 9 of 39 [23%], P = .009), lower left ventricular ejection fraction (mean [SD], 55% [4%] vs 62% [5%], P < .001), worse global longitudinal and circumferential strain (mean [SD], -16% [2%] vs -17% [2%], P = .02 and -18% [2%] vs -20% [2%], P = .047, respectively), and higher systemic inflammatory blood markers including interleukin 6, interleukin 8, and high-sensitivity C-reactive protein. Among patients with focal FDG uptake, PET/MRI, and inflammatory blood markers resolved or improved at follow-up performed a mean (SD) of 52 (17) days after baseline PET/MRI. CONCLUSIONS AND RELEVANCE: In this study of patients recently recovered from COVID-19, myocardial inflammation was identified on PET in a small proportion of patients, was associated with cardiac MRI abnormalities and elevated inflammatory blood markers at baseline, and improved at follow-up.
IMPORTANCE: Although myocardial injury can occur with acute COVID-19, there is limited understanding of changes with myocardial metabolism in recovered patients. OBJECTIVE: To examine myocardial metabolic changes early after recovery from COVID-19 using fluorodeoxyglucose-positron emission tomography (PET) and associate these changes to abnormalities in cardiac magnetic resonance imaging (MRI)-based function and tissue characterization measures and inflammatory blood markers. DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort study took place at a single-center tertiary referral hospital system. A volunteer sample of adult patients within 3 months of a diagnosis of COVID-19 who responded to a mail invitation were recruited for cardiac PET/MRI and blood biomarker evaluation between November 2020 and June 2021. EXPOSURES: Myocardial inflammation as determined by focal fluorodeoxyglucose (FDG) uptake on PET. MAIN OUTCOMES AND MEASURES: Demographic characteristics, cardiac and inflammatory blood markers, and fasting combined cardiac 18F-FDG PET/MRI imaging were obtained. All patients with focal FDG uptake at baseline returned for repeated PET/MRI and blood marker assessment 2 months later. RESULTS: Of 47 included patients, 24 (51%) were female, and the mean (SD) age was 43 (13) years. The mean (SD) interval between COVID-19 diagnosis and PET/MRI was 67 (16) days. Most patients recovered at home during the acute infection (40 [85%]). Eight patients (17%) had focal FDG uptake on PET consistent with myocardial inflammation. Compared with those without FDG uptake, patients with focal FDG uptake had higher regional T2, T1, and extracellular volume (colocalizing with focal FDG uptake), higher prevalence of late gadolinium enhancement (6 of 8 [75%] vs 9 of 39 [23%], P = .009), lower left ventricular ejection fraction (mean [SD], 55% [4%] vs 62% [5%], P < .001), worse global longitudinal and circumferential strain (mean [SD], -16% [2%] vs -17% [2%], P = .02 and -18% [2%] vs -20% [2%], P = .047, respectively), and higher systemic inflammatory blood markers including interleukin 6, interleukin 8, and high-sensitivity C-reactive protein. Among patients with focal FDG uptake, PET/MRI, and inflammatory blood markers resolved or improved at follow-up performed a mean (SD) of 52 (17) days after baseline PET/MRI. CONCLUSIONS AND RELEVANCE: In this study of patients recently recovered from COVID-19, myocardial inflammation was identified on PET in a small proportion of patients, was associated with cardiac MRI abnormalities and elevated inflammatory blood markers at baseline, and improved at follow-up.
Authors: Manuel D Cerqueira; Neil J Weissman; Vasken Dilsizian; Alice K Jacobs; Sanjiv Kaul; Warren K Laskey; Dudley J Pennell; John A Rumberger; Thomas Ryan; Mario S Verani Journal: Circulation Date: 2002-01-29 Impact factor: 29.690
Authors: Ludwig T Weckbach; Adrian Curta; Stephanie Bieber; Angelina Kraechan; Johannes Brado; Johannes C Hellmuth; Maximilian Muenchhoff; Clemens Scherer; Ines Schroeder; Michael Irlbeck; Stefan Maurus; Jens Ricke; Karin Klingel; Stefan Kääb; Mathias Orban; Steffen Massberg; Jörg Hausleiter; Ulrich Grabmaier Journal: Circ Cardiovasc Imaging Date: 2021-01-19 Impact factor: 7.792
Authors: Shobhit Mathur; John G Dreisbach; Gauri R Karur; Robert M Iwanochko; Chantal F Morel; Syed Wasim; Elsie T Nguyen; Bernd J Wintersperger; Kate Hanneman Journal: J Cardiovasc Magn Reson Date: 2019-08-01 Impact factor: 5.364
Authors: Jeanette Schulz-Menger; David A Bluemke; Jens Bremerich; Scott D Flamm; Mark A Fogel; Matthias G Friedrich; Raymond J Kim; Florian von Knobelsdorff-Brenkenhoff; Christopher M Kramer; Dudley J Pennell; Sven Plein; Eike Nagel Journal: J Cardiovasc Magn Reson Date: 2020-03-12 Impact factor: 5.364
Authors: Tushar Kotecha; Daniel S Knight; Yousuf Razvi; Kartik Kumar; Kavitha Vimalesvaran; George Thornton; Rishi Patel; Liza Chacko; James T Brown; Clare Coyle; Donald Leith; Abhishek Shetye; Ben Ariff; Robert Bell; Gabriella Captur; Meg Coleman; James Goldring; Deepa Gopalan; Melissa Heightman; Toby Hillman; Luke Howard; Michael Jacobs; Paramjit S Jeetley; Prapa Kanagaratnam; Onn Min Kon; Lucy E Lamb; Charlotte H Manisty; Palmira Mathurdas; Jamil Mayet; Rupert Negus; Niket Patel; Iain Pierce; Georgina Russell; Anthony Wolff; Hui Xue; Peter Kellman; James C Moon; Thomas A Treibel; Graham D Cole; Marianna Fontana Journal: Eur Heart J Date: 2021-05-14 Impact factor: 29.983
Authors: Felipe Sanchez Tijmes; Paaladinesh Thavendiranathan; Jacob A Udell; Michael A Seidman; Kate Hanneman Journal: Radiol Cardiothorac Imaging Date: 2021-11-18
Authors: Dmitrij Kravchenko; Alexander Isaak; Sebastian Zimmer; Narine Mesropyan; Matthäus Reinert; Anton Faron; Claus C Pieper; Annkristin Heine; Markus Velten; Jacob Nattermann; Daniel Kuetting; Georg D Duerr; Ulrike I Attenberger; Julian A Luetkens Journal: Radiology Date: 2021-08-10 Impact factor: 11.105
Authors: Constantin A Marschner; Kirsten E Shaw; Felipe Sanchez Tijmes; Matteo Fronza; Sharmila Khullar; Michael A Seidman; Paaladinesh Thavendiranathan; Jacob A Udell; Rachel M Wald; Kate Hanneman Journal: Cardiol Clin Date: 2022-05-06 Impact factor: 2.410
Authors: Ty J Gluckman; Nicole M Bhave; Larry A Allen; Eugene H Chung; Erica S Spatz; Enrico Ammirati; Aaron L Baggish; Biykem Bozkurt; William K Cornwell; Kimberly G Harmon; Jonathan H Kim; Anuradha Lala; Benjamin D Levine; Matthew W Martinez; Oyere Onuma; Dermot Phelan; Valentina O Puntmann; Saurabh Rajpal; Pam R Taub; Amanda K Verma Journal: J Am Coll Cardiol Date: 2022-03-16 Impact factor: 27.203
Authors: Dakota Gustafson; Michelle Ngai; Ruilin Wu; Huayun Hou; Alice Carvalhal Schoffel; Clara Erice; Serena Mandla; Filio Billia; Michael D Wilson; Milica Radisic; Eddy Fan; Uriel Trahtemberg; Andrew Baker; Chris McIntosh; Chun-Po S Fan; Claudia C Dos Santos; Kevin C Kain; Kate Hanneman; Paaladinesh Thavendiranathan; Jason E Fish; Kathryn L Howe Journal: EBioMedicine Date: 2022-04-08 Impact factor: 11.205
Authors: Lucas M Kimmig; Zvonimir A Rako; Susanne Herold; Khodr Tello; Ulrich Matt; Stefanie Ziegler; Manuel J Richter; Ashkan Tolou G S; Fritz Roller; Friedrich Grimminger; István Vadász; Werner Seeger Journal: Respir Res Date: 2022-09-21